In the phase 3 COMBI-i study, patients with advanced stage IIIC-IV cutaneous BRAFV600-mutant melanoma were randomly assigned to receive anti-PD-1 (spartalizumab) in combination with dabrafenib and trametinib, or dabrafenib/trametinib [32]. Here, PDCD1 is linked to melanoma.